ClinicaliQ Trial Snapshot
- Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes — Recruiting • Phase III • Diabetes / Metabolic • NCT07284875.
- Treatment being tested: KAI-9531, a novel subcutaneous injection administered weekly, is being evaluated for its efficacy in reducing body weight compared to placebo in patients with obesity or overweight status.
- Patient eligibility overview: The trial includes adults living with obesity or overweight who have weight-related comorbidities (such as hypertension or dyslipidaemia) but specifically excludes those with diabetes, allowing assessment of the drug's effects in a distinct patient population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Eligibility Snapshot
- : * BMI ≥30 kg/m^2 or BMI ≥27 kg/m^2 and previously diagnosed with at least 1 of the following: 1. hypertension, 2. dyslipidemia, 3. obstructive sleep apnea, or 4. cardiovascular (CV) disease. * History of at least 1 self-reported unsuccessful effort to lose weight with diet and exercise within the prior 6 months.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.